Insys Therapeutics missed analysts’ estimates in its latest quarter and set aside roughly $150 million to cover potential settlement costs, following news that its co-founder and former CEO had been charged with conspiracy.
from WSJ.com: US Business http://ift.tt/2zqhNKZ
via IFTTT
No comments:
Post a Comment